Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of antidiabetic agents known to exert cardioprotective, renoprotective, and hypoglycemic effects. However, these agents have been associated with adverse effects, such as genital infection, volume depletion, hypoglycemia, and diabetic k...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/22/6993 |
| _version_ | 1797458865579622400 |
|---|---|
| author | Yuto Saijo Hiroshi Okada Shinnosuke Hata Hanako Nakajima Nobuko Kitagawa Takuro Okamura Takafumi Osaka Noriyuki Kitagawa Saori Majima Takafumi Senmaru Emi Ushigome Naoko Nakanishi Masahide Hamaguchi Michiaki Fukui |
| author_facet | Yuto Saijo Hiroshi Okada Shinnosuke Hata Hanako Nakajima Nobuko Kitagawa Takuro Okamura Takafumi Osaka Noriyuki Kitagawa Saori Majima Takafumi Senmaru Emi Ushigome Naoko Nakanishi Masahide Hamaguchi Michiaki Fukui |
| author_sort | Yuto Saijo |
| collection | DOAJ |
| description | Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of antidiabetic agents known to exert cardioprotective, renoprotective, and hypoglycemic effects. However, these agents have been associated with adverse effects, such as genital infection, volume depletion, hypoglycemia, and diabetic ketoacidosis, resulting in drug discontinuation. Herein, we aimed to determine the reasons for discontinuing treatment with SGLT2is among Japanese patients with diabetes. This retrospective cohort study enrolled 766 patients with diabetes who had initiated SGLT2is between January 2014 and September 2021. The follow-up period was 2 years from the initiation of the SGLT2is. Overall, 97 patients (12.7%) discontinued the SGLT2is during the follow-up period. The most common reasons for discontinuing the SGLT2is were frequent urination (19.6%), followed by genital infection (11.3%), improved glycemic control (10.6%), and renal dysfunction (8.2%). A comparison of the characteristics between the continuation and the discontinuation group was conducted, excluding those who discontinued the SGLT2is because of improved glycemic control. The patients in the discontinuation group (68 [55–75] years) were older than those in the continuation group (64 [53–71] years; <i>p</i> = 0.003). Importantly, we found no significant association between diabetes duration, diabetic control, renal function, or complications of diabetes in both groups. This real-world study revealed that frequent urination was the most common reason underlying SGLT2i discontinuation among Japanese patients with diabetes. To avoid discontinuation, precautions against various factors that may cause frequent urination must be implemented. |
| first_indexed | 2024-03-09T16:44:17Z |
| format | Article |
| id | doaj.art-b653fdf137184e94a633ffff1eaa99ca |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T16:44:17Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-b653fdf137184e94a633ffff1eaa99ca2023-11-24T14:49:04ZengMDPI AGJournal of Clinical Medicine2077-03832023-11-011222699310.3390/jcm12226993Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A StudyYuto Saijo0Hiroshi Okada1Shinnosuke Hata2Hanako Nakajima3Nobuko Kitagawa4Takuro Okamura5Takafumi Osaka6Noriyuki Kitagawa7Saori Majima8Takafumi Senmaru9Emi Ushigome10Naoko Nakanishi11Masahide Hamaguchi12Michiaki Fukui13Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanSodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of antidiabetic agents known to exert cardioprotective, renoprotective, and hypoglycemic effects. However, these agents have been associated with adverse effects, such as genital infection, volume depletion, hypoglycemia, and diabetic ketoacidosis, resulting in drug discontinuation. Herein, we aimed to determine the reasons for discontinuing treatment with SGLT2is among Japanese patients with diabetes. This retrospective cohort study enrolled 766 patients with diabetes who had initiated SGLT2is between January 2014 and September 2021. The follow-up period was 2 years from the initiation of the SGLT2is. Overall, 97 patients (12.7%) discontinued the SGLT2is during the follow-up period. The most common reasons for discontinuing the SGLT2is were frequent urination (19.6%), followed by genital infection (11.3%), improved glycemic control (10.6%), and renal dysfunction (8.2%). A comparison of the characteristics between the continuation and the discontinuation group was conducted, excluding those who discontinued the SGLT2is because of improved glycemic control. The patients in the discontinuation group (68 [55–75] years) were older than those in the continuation group (64 [53–71] years; <i>p</i> = 0.003). Importantly, we found no significant association between diabetes duration, diabetic control, renal function, or complications of diabetes in both groups. This real-world study revealed that frequent urination was the most common reason underlying SGLT2i discontinuation among Japanese patients with diabetes. To avoid discontinuation, precautions against various factors that may cause frequent urination must be implemented.https://www.mdpi.com/2077-0383/12/22/6993sodium-glucose cotransporter 2 (SGLT2) inhibitorsdiabetesdrug discontinuation |
| spellingShingle | Yuto Saijo Hiroshi Okada Shinnosuke Hata Hanako Nakajima Nobuko Kitagawa Takuro Okamura Takafumi Osaka Noriyuki Kitagawa Saori Majima Takafumi Senmaru Emi Ushigome Naoko Nakanishi Masahide Hamaguchi Michiaki Fukui Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study Journal of Clinical Medicine sodium-glucose cotransporter 2 (SGLT2) inhibitors diabetes drug discontinuation |
| title | Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study |
| title_full | Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study |
| title_fullStr | Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study |
| title_full_unstemmed | Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study |
| title_short | Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study |
| title_sort | reasons for discontinuing treatment with sodium glucose cotransporter 2 inhibitors in patients with diabetes in real world settings the kamogawa a study |
| topic | sodium-glucose cotransporter 2 (SGLT2) inhibitors diabetes drug discontinuation |
| url | https://www.mdpi.com/2077-0383/12/22/6993 |
| work_keys_str_mv | AT yutosaijo reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT hiroshiokada reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT shinnosukehata reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT hanakonakajima reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT nobukokitagawa reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT takurookamura reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT takafumiosaka reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT noriyukikitagawa reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT saorimajima reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT takafumisenmaru reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT emiushigome reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT naokonakanishi reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT masahidehamaguchi reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy AT michiakifukui reasonsfordiscontinuingtreatmentwithsodiumglucosecotransporter2inhibitorsinpatientswithdiabetesinrealworldsettingsthekamogawaastudy |